Johan Harmenberg to be replaced by Klaas Bakker as Oncopeptides CMO
Swedish biotech Oncopeptides (Nasdaq Stockholm: ONCO) has poached AstraZeneca's (LSE: AZN) Klaas Bakker (pictured below) to replace Johan Harmenberg (pictured above) as its new chief medical officer (CMO).
Dr Harmenberg has reached retirement age and as Oncopeptides continues to expand its activities, has decided to step down as CMO but to continue to work as a member of the company's medical team.
From 2015 to present, Dr Bakker has worked at AstraZeneca in different roles with increasing responsibility and seniority, most recently as vice president, global medical franchise head for Tagrisso (osimertinib), the blockbuster cancer drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze